ArticleJOR spine2025
An Ex Vivo Model of Intervertebral Disc Degeneration for Assessing Retention of Injectable Cell-Based Grafts.
Article in JOR spine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cell therapies for painful intervertebral disc (IVD) degeneration (IDD) have not yet achieved widespread clinical adoption. Understanding therapeutic cell effects in native IVD remains challenging due to the complex IVD environment and limitations of current models. We present a physiologically relevant ex vivo model of IVD degeneration, which we employ to evaluate the retention of therapeutic cells in the IVD. Methods: Bovine IVDs were cultured ex vivo for 14 days. IVD degeneration was induced under physiological loading by chondroitinase ABC (ChABC), or ChABC with pro-inflammatory cytokines (Infl) aiming to mimic IDD. The nucleus pulposus (NP) tissue integrity was characterized by T2 MRI and modified Thompson grading and compared with human IVDs of different ages. The onset of IDD in the bovine model was assessed by IL-8, MMP13, and COX-2 expression. Spheroids derived from mCherry-transduced human nasal chondrocytes (NCS) were injected into the NP. NCS retention within the IDD model was assessed by NCS ability to survive (c-caspase 3), localize (mCherry), and produce chondrogenic proteins (SOX-9, aggrecan). Results: ChABC injection reduced water and proteoglycan content in the NP, resembling human age-related IVD degeneration. ChABC + Infl treatment led to a more pronounced loss of tissue integrity and upregulation of IL-8, MMP13, and COX-2, typically characterizing the transition to IDD. Upon injection into the IDD model, NCS localized in the NP, some remained viable, and maintained their chondrogenic features, demonstrating successful retention within the 7-day time frame. Conclusion: We developed an ex vivo IVD model with a controlled and physiologically relevant environment and used it for assessing the retention of cell-based therapies for NP repair. The model recapitulated the progression of IVD degeneration, establishing its value as a preclinical research tool and reducing the reliance on animal studies during the early translational phase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.